Altria Stock (MO) News: Dividend Reset, FDA on! PLUS Authorization, and NJOY Legal Battle

NEW YORK, Dec. 28, 2025, 2:59 PM ET — Market closed

Altria Group, Inc. (NYSE: MO) stock heads into the final week of 2025 with investors balancing three key forces: a just-passed ex-dividend reset that can distort short-term price action, a notable regulatory win for its on! PLUS nicotine pouches, and continued legal crosscurrents tied to its NJOY e-vapor business.

With U.S. markets closed for the weekend, Monday’s open will bring the first chance to reposition after Friday’s holiday-thin session—just as Wall Street watches whether the year-end “Santa Claus rally” carries into early January, and whether upcoming Federal Reserve minutes add clarity to the 2026 rate path. ^[1]

Altria stock price today: where MO closed, and what changed after-hours

Altria shares last traded at $57.60, down about 2.33% in the most recent session, with the day’s range spanning roughly $57.41 to $58.17 on volume near 9.0 million shares.

Extended-hours indications were little changed, with some feeds showing MO around $57.64 after the regular close. ^[2]

Quick snapshot for investors

Ticker / Exchange: MO / NYSE ^[3]
Last close: $57.60
Latest after-hours indication: ~ $57.64 ^[4]
Next dividend payment: $1.06 per share, payable Jan. 9, 2026 ^[5]
Next earnings (widely tracked estimate):Jan. 29, 2026 (before open) ^[6]
Street view (MarketBeat compilation): “Hold” consensus; average price target $62.33 ^[7]

Why MO dropped Friday: the ex-dividend “reset” factor

Friday (Dec. 26) was Altria’s ex-dividend date for its most recently declared quarterly payout. Altria’s board declared a $1.06 quarterly dividend payable Jan. 9, 2026, to shareholders of record as of Dec. 26, 2025, with the ex-dividend date also Dec. 26. ^[8]

That detail matters because, all else equal, stocks often open lower on the ex-dividend date by roughly the dividend amount—an adjustment that can make a dividend stock look suddenly weak in price terms even when the total return picture is more stable. A Nasdaq dividend note ahead of the date highlighted the same dynamic for Altria, flagging that MO would be expected to trade lower on the ex-date by approximately the dividend’s size. ^[9]

In practical terms: if you’re comparing Altria’s Friday close to prior closes without adjusting for the dividend, you can overstate the “real” selling pressure.

The most relevant MO headlines from the last 24–48 hours

While there have been no major new Altria corporate press releases over the weekend, several developments in the past 1–2 days frame Monday’s setup:

1) NJOY vs. Juul legal fight: discovery dispute spotlights patent pressure

In the most recent legal update, Juul Labs asked a federal judge to block Altria and its NJOY units from using certain documents Juul says were inadvertently made public, arguing the records could affect a nicotine-salt vape patent dispute. NJOY opposed the request and alleged Juul was trying to keep damaging evidence out of discovery, according to a joint dispute filing referenced in the report. ^[10]

Why investors care: NJOY’s ability to compete (and to protect its IP position) remains a swing factor in Altria’s “Moving Beyond Smoking” strategy—especially after prior disruptions in the vape category.

2) Institutional positioning: a new 13F-based update

A MarketBeat filing summary published within the past day reported Cwm LLC increased its stake in Altria during the third quarter, based on a 13F filing. ^[11]

This kind of item is rarely a single-session catalyst by itself, but it feeds the broader “who owns the stock and how are holders behaving” narrative—particularly for a high-yield, defensive name where institutional demand can stabilize drawdowns.

3) Market backdrop into Monday: year-end momentum, Fed minutes, and rotation watch

The broader market context is important for MO because dividend-heavy defensives often trade in sympathy with shifting rate expectations and late-December positioning. In its Week Ahead outlook, Reuters noted the S&P 500 was hovering near record levels and within reach of 7,000, while investors focus on Fed minutes and whether recent rotation into non-tech areas continues. ^[12]

Reuters also quoted multiple strategists on the year-end setup and rate sensitivity, including:

Paul Nolte (Murphy & Sylvest Wealth Management) on bullish momentum, ^[13]
Michael Reynolds (Glenmede) on why Fed minutes could be “illuminating” for the 2026 rate path, ^[14]
Anthony Saglimbene (Ameriprise Financial) on rotation and valuation dynamics. ^[15]

And in Friday’s quiet, post-holiday session recap, Reuters cited Ryan Detrick (Carson Group) on the “Santa Claus rally” window and the idea that markets were “catching our breath” after a strong run. ^[16]

The bigger MO catalysts investors are still pricing in

Even if the last 48 hours were light on fresh company announcements, several December developments continue to shape the forward narrative:

FDA authorization for on! PLUS nicotine pouches

A key positive for Altria’s smoke-free ambitions arrived when the U.S. FDA authorized marketing for six Altria-owned on! PLUS nicotine pouch products, under a pilot program aimed at speeding review. Reuters reported the decision covers mint, tobacco, and wintergreen variants in 6 mg and 9 mg strengths, and that Altria told Reuters on! PLUS would resume taking new orders for retail accounts in select states and via e-commerce. ^[17]

Retail and convenience-channel coverage also emphasized the authorization as a meaningful milestone for Altria’s modern oral portfolio. ^[18]

Why it matters: nicotine pouches have been one of the fastest-growing nicotine categories in the U.S., and FDA authorizations help legitimize product access and distribution—an advantage versus gray-market competitors. ^[19]

CEO succession plan set for 2026

Altria has also telegraphed leadership continuity. The company announced CEO Billy Gifford plans to retire effective May 14, 2026, with the board electing CFO Salvatore (Sal) Mancuso to succeed him. The press release also stated Heather Newman will become CFO at the same time, and board chair Kathryn McQuade highlighted the board’s view of Mancuso’s industry knowledge and fit with Altria’s 2028 goals. ^[20]

Forecasts and analysis: what Wall Street is modeling for MO

Analyst consensus: “Hold,” with price targets centered in the low $60s

MarketBeat’s compilation of 11 analyst ratings places Altria at a “Hold” consensus, with an average 12‑month price target of $62.33 (high $72, low $50). ^[21]

At the current quote used in that compilation, that implies mid-single-digit to high-single-digit upside potential—before factoring in the dividend stream.

Earnings path: Jan. 29 is the key near-term checkpoint

Altria has not formally confirmed its next earnings date in every public calendar, but multiple widely followed market schedules peg the next report around Jan. 29, 2026. TipRanks lists Jan. 29, 2026 (before open) as the scheduled report timing, and MarketBeat lists the same date as an estimate based on historical reporting patterns. ^[22]

Company guidance and capital return remain central to the bull case

In its Q3 release, Altria said it narrowed full-year 2025 adjusted diluted EPS guidance to $5.37–$5.45, and it highlighted shareholder returns— including an expansion of its share repurchase authorization from $1 billion to $2 billion, now expiring Dec. 31, 2026. ^[23]

That same release reiterated its current annualized dividend rate of $4.24 per share and referenced its long history of dividend increases. ^[24]

On the cautionary side, Reuters previously reported that Altria’s outlook has faced pressure from sluggish tobacco demand and challenges in smoke-free products, including NJOY disruptions tied to patent disputes. ^[25]

If MO is on your watchlist: what to know before the next session opens

Because the NYSE is closed today, the practical question becomes: what can change before Monday?

1) Don’t misread ex-dividend price action

If you’re reviewing charts or performance screens, remember MO is now trading ex-dividend for the $1.06 payment. Investors who purchased on or after Dec. 26 generally won’t receive the upcoming Jan. 9 dividend. ^[26]

2) Watch the macro calendar—especially Fed minutes—in a thin year-end tape

Late December trading can amplify moves because liquidity is often lighter. Reuters flagged that Fed minutes and year-end portfolio adjustments could drive volatility even with limited catalysts, and strategists emphasized that momentum has favored bulls—until an “exogenous event” changes the equation. ^[27]

For MO specifically, shifts in rate expectations matter because many investors compare high-yield equities to bond yields when deciding where to park capital.

3) Track NJOY litigation and trade actions as “headline risk”

Two separate legal lanes are worth monitoring:

The Juul discovery dispute (Arizona federal court) reported by Bloomberg Law. ^[28]
A related trade/legal front: the U.S. International Trade Commission instituted an investigation based on a complaint filed by NJOY, LLC and Altria entities, seeking potential exclusion and cease-and-desist relief tied to alleged patent infringement involving vaporizer devices and cartridges. ^[29]

These are not daily-trading drivers until a court or agency ruling hits—but they shape expectations for whether NJOY can scale (and how quickly).

4) Follow the rollout and regulatory runway for on! PLUS

The FDA authorization is a clear fundamental tailwind for Altria’s modern oral portfolio, and investors will be looking for signs that distribution expands beyond initial geographies and that the pilot program leads to more timely decisions. ^[30]

5) Keep Jan. 29 circled for guidance, buyback cadence, and smoke-free updates

Even in a “steady” dividend stock, earnings can re-rate the shares quickly—especially if management commentary changes around:

smoke-free product progress,
NJOY timing and economics,
and capital allocation (repurchases vs. debt vs. dividends). ^[31]

Bottom line

Altria enters the next session with the stock price reflecting an ex-dividend adjustment, while the longer-term debate remains intact: can MO keep converting its cash-flow engine into durable shareholder returns while building credible smoke-free growth—through regulatory wins like on! PLUS, and despite ongoing vapor litigation complexity around NJOY?

Monday’s open is less about a single headline and more about whether the year-end market mood (risk-on momentum, rate-cut expectations, and rotation) supports income names—and whether MO’s catalysts can keep investors focused on total return, not just Friday’s drop. ^[32]